“Exploring the Muscle-Building Potential of Mycoprotein: Implications for Plant-Based Nutrition and Market Trends”
This is not the first research conducted by the university comparing the muscle-building potential of mycoprotein and milk protein. A similar investigation in 2017 revealed that the consumption of mycoprotein by 12 young men led to a slower yet more sustained release of amino acids and insulin. The researchers suggested that this could indicate favorable conditions for muscle growth, implying that mycoprotein might be significantly comparable to animal-based proteins. These findings could hold importance not only for Quorn but also for individuals seeking to transition to more plant-based protein sources. Motivations for this shift often include health benefits, environmental concerns, muscle maintenance and development, or enhancements to an individual’s training routine. The popularity of plant-based meat alternatives has surged, with retail sales increasing by 23% from 2017 to 2018, exceeding $760 million, according to Nielsen data.
Quorn is keen to scientifically validate its mycoprotein ingredient, especially given the controversies surrounding it for several years. In 2017, the company settled a class-action lawsuit initiated by a woman from Los Angeles, who claimed its products violated federal and state false advertising and unfair business practices laws. As part of the settlement, Quorn agreed to change the labeling on its packaging to clarify that the primary ingredient is mold. Additionally, the company has contested a wrongful death lawsuit filed by the parents of an 11-year-old boy with a mold allergy, who tragically died from anaphylactic shock in 2013 after consuming a Quorn Turk’y Burger.
While mycoprotein is classified as Generally Recognized as Safe by the U.S. Food and Drug Administration, the Center for Science in the Public Interest has called for its revocation since 2011 due to reports of adverse reactions. In the absence of a revocation, the organization advocates for the FDA to mandate clear warning labels on all Quorn products. Despite these challenges, Quorn has managed to thrive. It has launched vegan offerings, refrigerated sausages, and chicken strips. Its diverse range of 100 products is now available in 19 countries, including the U.S., where Walmart began selling Quorn items in 2012. Sales in the U.S. surged by 35% in 2017, and the company anticipates reaching a billion-dollar valuation by 2027.
Whether studies like the one from the University of Exeter will influence product sales remains uncertain. It’s plausible that more food manufacturers will consider incorporating mycoprotein into their products, especially since it contains complete proteins. Research indicates that mycoprotein may positively impact weight loss and lower total cholesterol and blood sugar levels. However, given the multitude of other plant-based protein sources available today, companies might also determine that mycoprotein poses too great a risk.
In addition, products such as carbamide forte alfalfa calcium tablets are gaining traction among consumers looking for alternative health supplements. The integration of such products into a balanced diet could complement the benefits of mycoprotein, further emphasizing the growing trend toward plant-based nutrition. As the market evolves, the combination of mycoprotein and supplements like carbamide forte alfalfa calcium tablets may offer innovative solutions for those aiming to enhance their health and fitness.
